Is label-free LC-MS/MS ready for biomarker discovery?
(2015) In Proteomics Clinical Applications 9(3-4). p.289-294- Abstract
- Label-free LC-MS methods are attractive for high-throughput quantitative proteomics, as the sample processing is straightforward and can be scaled to a large number of samples. Label-free methods therefore facilitate biomarker discovery in studies involving dozens of clinical samples. However, despite the increased popularity of label-free workflows, there is a hesitance in the research community to use it in clinical proteomics studies. Therefore, we here discuss pros and cons of label free LC-MS/MS for biomarker discovery, and delineate the main prerequisites for its successful employment. Furthermore, we cite studies where label-free LC-MS/MS was successfully used to identify novel biomarkers, and foresee an increased acceptance of... (More)
- Label-free LC-MS methods are attractive for high-throughput quantitative proteomics, as the sample processing is straightforward and can be scaled to a large number of samples. Label-free methods therefore facilitate biomarker discovery in studies involving dozens of clinical samples. However, despite the increased popularity of label-free workflows, there is a hesitance in the research community to use it in clinical proteomics studies. Therefore, we here discuss pros and cons of label free LC-MS/MS for biomarker discovery, and delineate the main prerequisites for its successful employment. Furthermore, we cite studies where label-free LC-MS/MS was successfully used to identify novel biomarkers, and foresee an increased acceptance of label-free techniques by the proteomics community in the near future. This article is protected by copyright. All rights reserved. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5145330
- author
- Sandin, Marianne LU ; Chawade, Aakash LU and Levander, Fredrik LU
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Proteomics Clinical Applications
- volume
- 9
- issue
- 3-4
- pages
- 289 - 294
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- pmid:25656266
- wos:000353291000005
- scopus:84928062047
- pmid:25656266
- ISSN
- 1862-8354
- DOI
- 10.1002/prca.201400202
- language
- English
- LU publication?
- yes
- id
- ea083c77-821c-48fc-a681-ceb66c0a591e (old id 5145330)
- date added to LUP
- 2016-04-01 10:26:57
- date last changed
- 2022-04-04 18:08:17
@misc{ea083c77-821c-48fc-a681-ceb66c0a591e,
abstract = {{Label-free LC-MS methods are attractive for high-throughput quantitative proteomics, as the sample processing is straightforward and can be scaled to a large number of samples. Label-free methods therefore facilitate biomarker discovery in studies involving dozens of clinical samples. However, despite the increased popularity of label-free workflows, there is a hesitance in the research community to use it in clinical proteomics studies. Therefore, we here discuss pros and cons of label free LC-MS/MS for biomarker discovery, and delineate the main prerequisites for its successful employment. Furthermore, we cite studies where label-free LC-MS/MS was successfully used to identify novel biomarkers, and foresee an increased acceptance of label-free techniques by the proteomics community in the near future. This article is protected by copyright. All rights reserved.}},
author = {{Sandin, Marianne and Chawade, Aakash and Levander, Fredrik}},
issn = {{1862-8354}},
language = {{eng}},
number = {{3-4}},
pages = {{289--294}},
publisher = {{John Wiley & Sons Inc.}},
series = {{Proteomics Clinical Applications}},
title = {{Is label-free LC-MS/MS ready for biomarker discovery?}},
url = {{https://lup.lub.lu.se/search/files/1853432/7472042.pdf}},
doi = {{10.1002/prca.201400202}},
volume = {{9}},
year = {{2015}},
}